US Pharmaceuticals Analyst Schott and Biotech Analyst Fye discuss the latest development in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL) (ABBV, ADCT, ALLO, AZN, BGNE, BMY, CCCC, CRGX, GILD, JNJ, LLY, NRIX, GMAB, RHHBY) on an Analyst/Industry conference call to be held on March 15 at 12 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- Allergan Aesthetics announces FDA approval of JUVEDERM VOLUMA XC
- AbbVie makes milestone payment to Dragonfly after dosing in solid tumor trial
- AbbVie, OSE Immunotherapeutics enter pact to develop OSE-230
- Regenxbio expects cash to fund operations into 2H25
- AbbVie’s epcoritamab granted priority review by FDA in follicular lymphoma
